114 related articles for article (PubMed ID: 35636320)
1. Hormone receptor binding, selectivity and cytotoxicity of steroid D-homo lactone loaded chitosan nanoparticles for the treatment of breast and prostate cancer cells.
Kuzminac IZ; Ćelić AS; Bekić SS; Kojić V; Savić MP; Ignjatović NL
Colloids Surf B Biointerfaces; 2022 Aug; 216():112597. PubMed ID: 35636320
[TBL] [Abstract][Full Text] [Related]
2. Preselection of A- and B- modified d-homo lactone and d-seco androstane derivatives as potent compounds with antiproliferative activity against breast and prostate cancer cells - QSAR approach and molecular docking analysis.
Kovačević SZ; Podunavac-Kuzmanović SO; Jevrić LR; Vukić VR; Savić MP; Djurendić EA
Eur J Pharm Sci; 2016 Oct; 93():107-13. PubMed ID: 27503457
[TBL] [Abstract][Full Text] [Related]
3. Antitumor potential of novel 5α,6β-dibromo steroidal D-homo lactone.
Kuzminac IZ; Bekić SS; Ćelić AS; Jakimov DS; Sakač MN
Steroids; 2022 Dec; 188():109118. PubMed ID: 36183814
[TBL] [Abstract][Full Text] [Related]
4. New steroidal lactones as 5α-reductase inhibitors and antagonists for the androgen receptor.
Garrido M; Bratoeff E; Bonilla D; Soriano J; Heuze Y; Cabeza M
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):367-73. PubMed ID: 21782943
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.
Kuzminac IZ; Jakimov DS; Bekić SS; Ćelić AS; Marinović MA; Savić MP; Raičević VN; Kojić VV; Sakač MN
Bioorg Med Chem; 2021 Jan; 30():115935. PubMed ID: 33340938
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
Nikolić AR; Petri ET; Klisurić OR; Ćelić AS; Jakimov DS; Djurendić EA; Penov Gaši KM; Sakač MN
Bioorg Med Chem; 2015 Feb; 23(4):703-11. PubMed ID: 25619894
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of A-ring fused pyridine d-modified androstane derivatives for antiproliferative and aldo-keto reductase 1C3 inhibitory activity.
Savić MP; Ajduković JJ; Plavša JJ; Bekić SS; Ćelić AS; Klisurić OR; Jakimov DS; Petri ET; Djurendić EA
Medchemcomm; 2018 Jun; 9(6):969-981. PubMed ID: 30108986
[TBL] [Abstract][Full Text] [Related]
8. Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor.
Ignjatović NL; Penov-Gaši KM; Wu VM; Ajduković JJ; Kojić VV; Vasiljević-Radović D; Kuzmanović M; Uskoković V; Uskoković DP
Colloids Surf B Biointerfaces; 2016 Dec; 148():629-639. PubMed ID: 27694053
[TBL] [Abstract][Full Text] [Related]
9. Development of new steroid-based hydrazide and (thio)semicarbazone compounds with anticancer properties.
Janković Ð; Šestić TL; Bekić SS; Savić MP; Ćelić AS; Scholda J; Kopp F; Marinović MA; Petri ET; Ajduković JJ
J Steroid Biochem Mol Biol; 2024 May; ():106545. PubMed ID: 38762058
[TBL] [Abstract][Full Text] [Related]
10. Identification of d-seco modified steroid derivatives with affinity for estrogen receptor α and β isoforms using a non-transcriptional fluorescent cell assay in yeast.
Bekić SS; Marinović MA; Petri ET; Sakač MN; Nikolić AR; Kojić VV; Ćelić AS
Steroids; 2018 Feb; 130():22-30. PubMed ID: 29224741
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of novel steroidal 6-substituted 4-en-3-one D-seco dinitriles.
Nikolić AR; Kuzminac IZ; Jovanović-Šanta SS; Jakimov DS; Aleksić LD; Sakač MN
Steroids; 2018 Jul; 135():101-107. PubMed ID: 29604312
[TBL] [Abstract][Full Text] [Related]
12. Chitosan Oligosaccharide Lactate Coated Hydroxyapatite Nanoparticles as a Vehicle for the Delivery of Steroid Drugs and the Targeting of Breast Cancer Cells.
Ignjatović NL; Sakač M; Kuzminac I; Kojić V; Marković S; Vasiljević-Radović D; Wu VM; Uskoković V; Uskoković DP
J Mater Chem B; 2018; 6(43):6957-6968. PubMed ID: 30931125
[TBL] [Abstract][Full Text] [Related]
13. Curcumin diethyl disuccinate encapsulated in chitosan/alginate nanoparticles for improvement of its
Bhunchu S; Muangnoi C; Rojsitthisak P; Rojsitthisak P
Pharmazie; 2016 Dec; 71(12):691-700. PubMed ID: 29441997
[TBL] [Abstract][Full Text] [Related]
14. Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells.
Sanderson T; Renaud M; Scholten D; Nijmeijer S; van den Berg M; Cowell S; Guns E; Nelson C; Mutarapat T; Ruchirawat S
Eur J Pharmacol; 2008 Sep; 593(1-3):92-8. PubMed ID: 18639541
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the Effect of Breast Cancer Patients' Plasma on the Targeting Ability of Folic Acid-Modified Chitosan Nanoparticles.
Nemati M; Bani F; Sepasi T; Zamiri RE; Rasmi Y; Kahroba H; Rahbarghazi R; Sadeghi MR; Wang Y; Zarebkohan A; Gao H
Mol Pharm; 2021 Dec; 18(12):4341-4353. PubMed ID: 34779630
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects and apoptosis induction of cisplatin-loaded iron oxide nanoparticles modified with chitosan in human breast cancer cells.
Morovati A; Ahmadian S; Jafary H
Mol Biol Rep; 2019 Oct; 46(5):5033-5039. PubMed ID: 31278563
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells.
Roy K; Patel YS; Kanwar RK; Rajkhowa R; Wang X; Kanwar JR
Int J Nanomedicine; 2016; 11():25-44. PubMed ID: 26730188
[TBL] [Abstract][Full Text] [Related]
19. In silico ADMET analysis of the A-, B- and D-modified androstane derivatives with potential anticancer effects.
Šestić TL; Ajduković JJ; Marinović MA; Petri ET; Savić MP
Steroids; 2023 Jan; 189():109147. PubMed ID: 36410412
[TBL] [Abstract][Full Text] [Related]
20. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
